Engineered T cells and their therapeutic applications in autoimmune diseases

作     者：Lei Bao Xiao-Chen Bo Huai-Wen Cao Chen Qian Zeng Wang Bin Li Lei Bao;Xiao-Chen Bo;Huai-Wen Cao;Chen Qian;Zeng Wang;Bin Li

作者机构：Department of Immunology and MicrobiologyShanghai Institute of ImmunologyShanghai Jiao Tong University School of MedicineShanghai Jiao Tong UniversityShanghai 200025China 

出 版 物：《Zoological Research》 (动物学研究（英文）)

年 卷 期：2022年第43卷第2期

页      面：150-165页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(81830051,31961133011,32130041) National Key R&D Program of China(2019YFA09006100) Shanghai Academic Research Leader(16XD1403800) Innovative Research Team of High-Level Local Universities in Shanghai Shanghai Collaborative Innovation Center of Cellular Homeostasis Regulation and Human Diseases 

主　　题：Chimeric antigen receptor T cells Cell immunotherapy Autoimmune diseases 

摘      要：Chimeric antigen receptor T cells(CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in the treatment of autoimmune ***, regulatory T cells(Treg), a subset of CD4 T cells exhibiting immunosuppressive functions,have attracted increasing attention regarding CARTreg cell production. In this review, we report on recent developments in preclinical and clinical studies on CAR-T cells in autoimmune diseases and provide an outlook on opportunities and challenges of CAR-T application in such diseases.